Thrivent Financial for Lutherans’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$69.6M Buy
1,147,974
+975,107
+564% +$56.8M 0.13% 179
2025
Q4
$9.23M Buy
172,867
+9,407
+6% +$453K 0.02% 694
2025
Q3
$7.37M Buy
163,460
+11,904
+8% +$556K 0.01% 719
2025
Q2
$7.02M Sell
151,556
-11,755
-7% -$577K 0.02% 692
2025
Q1
$9.91M Sell
163,311
-3,168
-2% -$185K 0.02% 616
2024
Q4
$9.45M Buy
166,479
+49,678
+43% +$2.78M 0.02% 677
2024
Q3
$6.04M Buy
116,801
+5,407
+5% +$254K 0.01% 850
2024
Q2
$4.63M Sell
111,394
-12,449
-10% -$557K 0.01% 930
2024
Q1
$6.72M Sell
123,843
-88,420
-42% -$4.5M 0.01% 776
2023
Q4
$10.9M Sell
212,263
-39,279
-16% -$2.06M 0.02% 615
2023
Q3
$14.6M Sell
251,542
-60,360
-19% -$3.7M 0.03% 494
2023
Q2
$19.9M Sell
311,902
-17,789
-5% -$1.19M 0.05% 433
2023
Q1
$22.8M Buy
329,691
+1,592
+0.5% +$112K 0.06% 389
2022
Q4
$23.6M Buy
328,099
+192,969
+143% +$14.6M 0.06% 372
2022
Q3
$9.61M Sell
135,130
-648
-0.5% -$47K 0.03% 599
2022
Q2
$10.5M Sell
135,778
-21,890
-14% -$1.67M 0.03% 594
2022
Q1
$11.4M Buy
157,668
+3,760
+2% +$252K 0.02% 644
2021
Q4
$9.77M Buy
153,908
+5,667
+4% +$332K 0.02% 679
2021
Q3
$8.87M Buy
148,241
+7,928
+6% +$522K 0.02% 709
2021
Q2
$9.38M Sell
140,313
-72
-0.1% -$4.7K 0.02% 702
2021
Q1
$8.86M Buy
140,385
+6,731
+5% +$419K 0.02% 698
2020
Q4
$8.29M Buy
133,654
+4,092
+3% +$252K 0.02% 700
2020
Q3
$7.81M Buy
129,562
+11,675
+10% +$703K 0.02% 673
2020
Q2
$6.88M Sell
117,887
-2,200
-2% -$132K 0.02% 636
2020
Q1
$6.68M Sell
120,087
-3,345
-3% -$204K 0.02% 590
2019
Q4
$7.92M Buy
123,432
+36,977
+43% +$2.12M 0.02% 627
2019
Q3
$4.38M Buy
86,455
+6,087
+8% +$286K 0.01% 717
2019
Q2
$3.65M Sell
80,368
-75,539
-48% -$3.52M 0.01% 762
2019
Q1
$7.44M Sell
155,907
-11,951
-7% -$595K 0.02% 573
2018
Q4
$8.84M Buy
167,858
+86,738
+107% +$4.66M 0.03% 489
2018
Q3
$5.04M Buy
81,120
+1,358
+2% +$80.6K 0.02% 648
2018
Q2
$4.41M Sell
79,762
-363
-0.5% -$19.6K 0.01% 676
2018
Q1
$5.07M Sell
80,125
-1,143
-1% -$73.5K 0.02% 645
2017
Q4
$4.98M Buy
81,268
+3,383
+4% +$212K 0.02% 642
2017
Q3
$4.96M Buy
77,885
+11,912
+18% +$696K 0.02% 607
2017
Q2
$3.68M Sell
65,973
-2,196,530
-97% -$120M 0.02% 668
2017
Q1
$123M Buy
2,262,503
+1,988,160
+725% +$109M 0.53% 41
2016
Q4
$16M Buy
274,343
+159,590
+139% +$8.72M 0.07% 272
2016
Q3
$6.2M Buy
114,753
+1,660
+1% +$107K 0.03% 512
2016
Q2
$8.33M Buy
113,093
+2,010
+2% +$142K 0.04% 429
2016
Q1
$7.11M Buy
111,083
+57,205
+106% +$3.61M 0.03% 462
2015
Q4
$3.71M Buy
53,878
+8,230
+18% +$544K 0.02% 684
2015
Q3
$2.7M Sell
45,648
-4,065
-8% -$258K 0.01% 719
2015
Q2
$3.32M Buy
49,713
+2,185
+5% +$144K 0.02% 566
2015
Q1
$3.06M Buy
47,528
+1,700
+4% +$106K 0.02% 596
2014
Q4
$2.72M Buy
45,828
+2,470
+6% +$139K 0.02% 619
2014
Q3
$2.21M Buy
43,358
+4,360
+11% +$218K 0.01% 662
2014
Q2
$1.89M Sell
38,998
-3,470
-8% -$171K 0.01% 718
2014
Q1
$2.21M Buy
42,468
+25
+0.1% +$1.33K 0.01% 576
2013
Q4
$2.26M Buy
42,443
+4,145
+11% +$211K 0.01% 573
2013
Q3
$1.77M Sell
38,298
-96,505
-72% -$4.24M 0.01% 609
2013
Q2
$6.03K Buy
+134,803
New +$5.85M 0.04% 397

Other funds holding BMY

Thrivent Financial for Lutherans's BMY Position: Q1 2026 in Review

Thrivent Financial for Lutherans increased its Bristol-Myers Squibb (BMY) stake by 564% in Q1 2026, buying an estimated $56.8M and bringing the position to 1,147,974 shares worth $69.6M. The position accounts for 0.13% of the portfolio, ranked #179.

Thrivent Financial for Lutherans first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $123M in Q1 2017. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Thrivent Financial for Lutherans held 1,147,974 shares of Bristol-Myers Squibb worth $69.6M as of Q1 2026.
  • Thrivent Financial for Lutherans bought 975,107 Bristol-Myers Squibb shares in Q1 2026, an estimated $56.8M.
  • Bristol-Myers Squibb made up 0.13% of Thrivent Financial for Lutherans's portfolio in Q1 2026, its #179 holding.
  • Thrivent Financial for Lutherans first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Thrivent Financial for Lutherans's Bristol-Myers Squibb position peaked at $123M in Q1 2017.
  • 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q1 2026, filed 1 May 2026.